LLY 📈 Eli Lilly and Company - Overview
Exchange: NYSE • Opening Hours • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5324571083
LLY: Insulin, Diabetes, Cancer, Arthritis, Obesity, Pain, Erectile Dysfunction
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, and markets a wide range of human pharmaceuticals. The company's product portfolio includes a variety of treatments for diabetes, such as Basaglar, Humalog, and Trulicity, as well as medications for type 2 diabetes, like Jardiance and Mounjaro. Additionally, Eli Lilly offers Zepbound for obesity management.
In the field of oncology, the company provides a range of products, including Alimta, Cyramza, Erbitux, and Verzenio, which are used to treat various types of cancer. Furthermore, Eli Lilly offers Olumiant for rheumatoid arthritis, atopic dermatitis, and other conditions, as well as Taltz for plaque psoriasis and psoriatic arthritis.
The company's product lineup also includes Omvoh for ulcerative colitis, Cymbalta for depressive disorder and chronic pain, Ebglyss for severe atopic dermatitis, and Emgality for migraine prevention. Moreover, Eli Lilly offers Cialis for erectile dysfunction and benign prostatic hyperplasia, as well as Forteo for osteoporosis treatment.
Eli Lilly operates the Lilly Seaport Innovation Center (LSC), a cutting-edge research and development facility in Boston, which focuses on advancing RNA and DNA-based therapies and discovering new drug targets. This facility enables the company to develop life-changing medicines across various disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain.
The company has established collaborations with several leading pharmaceutical companies, including Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, F. Hoffmann-La Roche Ltd, Genentech, Biologics, AbCellera Biologics, and Chugai Pharmaceutical Co. These partnerships enable Eli Lilly to leverage the expertise and resources of these companies to accelerate the development of innovative treatments.
Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. With a rich history spanning over 145 years, the company has established itself as a leader in the pharmaceutical industry, committed to developing and delivering innovative medicines that improve the lives of people around the world.
Additional Sources for LLY Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
LLY Stock Overview
| Market Cap in USD | 777,423m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| GiC SubIndustry | Pharmaceuticals |
| TER | 0.00% |
| IPO / Inception | 1978-01-13 |
LLY Stock Ratings
| Growth 5y | 96.9 |
| Fundamental | 57.2 |
| Dividend | 56.8 |
| Rel. Performance vs Sector | 1.22 |
| Analysts | 4.34/5 |
| Fair Price Momentum | 913.10 USD |
| Fair Price DCF | 22.33 USD |
LLY Dividends
| Dividend Yield 12m | 0.52% |
| Yield on Cost 5y | 3.54% |
| Dividends CAGR 5y | 11.87% |
| Payout Consistency | 99.53% |
LLY Growth Ratios
| Growth Correlation 3m | -80.6% |
| Growth Correlation 12m | 81.9% |
| Growth Correlation 5y | 98.9% |
| CAGR 5y | 46.86% |
| CAGR/Mean DD 5y | 8.76 |
| Sharpe Ratio 12m | 0.81 |
| Alpha vs SP500 12m | 4.94 |
| Beta vs SP500 5y weekly | 0.67 |
| Volatility GJR Garch 1y | 47.55% |
| Current Volume | 5153.3k |
| Average Volume 20d | 5416.9k |
As of November 21, 2024, the stock is trading at USD 753.41 with a total of 5,153,300 shares traded.
Over the past week, the price has changed by -7.04%, over one month by -16.72%, over three months by -20.56% and over the past year by +26.90%.
Partly, yes. Based on ValueRay Fundamental Analyses, Eli Lilly and Company (NYSE:LLY) is currently (November 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 57.16 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LLY as of November 2024 is 913.10. This means that LLY is currently undervalued and has a potential upside of +21.2% (Margin of Safety).
- Strong Buy: 17
- Buy: 7
- Hold: 4
- Sell: 0
- Strong Sell: 1
According to ValueRays Forecast Model, LLY Eli Lilly and Company will be worth about 1003.2 in November 2025. The stock is currently trading at 753.41. This means that the stock has a potential upside of +33.16%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 1008.1 | 33.8% |
| Analysts Target Price | 603.6 | -19.9% |
| ValueRay Target Price | 1003.2 | 33.2% |